FDA Issues New Draft Guidance on DCTs
Recommendations apply to where some or all the trial-related activities occur at locations other than traditional clinical trial sites.
The FDA announced new draft guidance that builds on its recommendations from March 2022 for clinical trial conduct in response to the COVID-19 public health emergency. This new draft guidance provides recommendations sponsors, investigators and other stakeholders regarding the implementation of decentralized clinical trials (DCTs) for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites.
FDA Commissioner Robert M. Califf, MD, said in a press release, “As we seek to improve our evidence generation system, decentralized clinical trials may enhance convenience for trial participants, reduce the burden on caregivers, expand access to more diverse populations, improve trial efficiencies, and facilitate research on rare diseases and diseases affecting populations with limited mobility.”
Reference: FDA Takes Additional Steps to Advance Decentralized Clinical Trials. FDA News Release, May 2, 2023.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
